Report cover image

Global Saxagliptin Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 180 Pages
SKU # APRC20278489

Description

Summary

According to APO Research, The global Saxagliptin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Saxagliptin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Saxagliptin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Saxagliptin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Saxagliptin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Saxagliptin include Bristol-Myers Squibb Company, Minxiang Pharma, Taizhou Canova Bio-technology, Tapi Teva, AstraZeneca, Hebei Kangtai Pharma, Huaman Xincaiiao Keji and Tianjin Scipharmacn, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Saxagliptin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Saxagliptin, also provides the sales of main regions and countries. Of the upcoming market potential for Saxagliptin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Saxagliptin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Saxagliptin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Saxagliptin sales, projected growth trends, production technology, application and end-user industry.

Saxagliptin Segment by Company

Bristol-Myers Squibb Company
Minxiang Pharma
Taizhou Canova Bio-technology
Tapi Teva
AstraZeneca
Hebei Kangtai Pharma
Huaman Xincaiiao Keji
Tianjin Scipharmacn
Saxagliptin Segment by Type

2.5mg
5mg
Saxagliptin Segment by Application

Hospital
Clinic
Others
Saxagliptin Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Saxagliptin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Saxagliptin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Saxagliptin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Saxagliptin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Saxagliptin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Saxagliptin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Saxagliptin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

180 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Saxagliptin Market Size, 2020 VS 2024 VS 2031
1.3 Global Saxagliptin Market Size Estimates and Forecasts (2020-2031)
1.4 Global Saxagliptin Sales Estimates and Forecasts (2020-2031)
1.5 Global Saxagliptin Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Saxagliptin Market Dynamics
2.1 Saxagliptin Industry Trends
2.2 Saxagliptin Industry Drivers
2.3 Saxagliptin Industry Opportunities and Challenges
2.4 Saxagliptin Industry Restraints
3 Saxagliptin Market by Manufacturers
3.1 Global Saxagliptin Revenue by Manufacturers (2020-2025)
3.2 Global Saxagliptin Sales by Manufacturers (2020-2025)
3.3 Global Saxagliptin Average Sales Price by Manufacturers (2020-2025)
3.4 Global Saxagliptin Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Saxagliptin Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Saxagliptin Manufacturers, Product Type & Application
3.7 Global Saxagliptin Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Saxagliptin Market CR5 and HHI
3.8.2 Global Top 5 and 10 Saxagliptin Players Market Share by Revenue in 2024
3.8.3 2024 Saxagliptin Tier 1, Tier 2, and Tier 3
4 Saxagliptin Market by Type
4.1 Saxagliptin Type Introduction
4.1.1 2.5mg
4.1.2 5mg
4.2 Global Saxagliptin Sales by Type
4.2.1 Global Saxagliptin Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Saxagliptin Sales by Type (2020-2031)
4.2.3 Global Saxagliptin Sales Market Share by Type (2020-2031)
4.3 Global Saxagliptin Revenue by Type
4.3.1 Global Saxagliptin Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Saxagliptin Revenue by Type (2020-2031)
4.3.3 Global Saxagliptin Revenue Market Share by Type (2020-2031)
5 Saxagliptin Market by Application
5.1 Saxagliptin Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Saxagliptin Sales by Application
5.2.1 Global Saxagliptin Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Saxagliptin Sales by Application (2020-2031)
5.2.3 Global Saxagliptin Sales Market Share by Application (2020-2031)
5.3 Global Saxagliptin Revenue by Application
5.3.1 Global Saxagliptin Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Saxagliptin Revenue by Application (2020-2031)
5.3.3 Global Saxagliptin Revenue Market Share by Application (2020-2031)
6 Global Saxagliptin Sales by Region
6.1 Global Saxagliptin Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Saxagliptin Sales by Region (2020-2031)
6.2.1 Global Saxagliptin Sales by Region (2020-2025)
6.2.2 Global Saxagliptin Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Saxagliptin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Saxagliptin Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Saxagliptin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Saxagliptin Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Saxagliptin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Saxagliptin Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Saxagliptin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Saxagliptin Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Saxagliptin Revenue by Region
7.1 Global Saxagliptin Revenue by Region
7.1.1 Global Saxagliptin Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Saxagliptin Revenue by Region (2020-2025)
7.1.3 Global Saxagliptin Revenue by Region (2026-2031)
7.1.4 Global Saxagliptin Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Saxagliptin Revenue (2020-2031)
7.2.2 North America Saxagliptin Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Saxagliptin Revenue (2020-2031)
7.3.2 Europe Saxagliptin Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Saxagliptin Revenue (2020-2031)
7.4.2 Asia-Pacific Saxagliptin Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Saxagliptin Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Saxagliptin Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Bristol-Myers Squibb Company
8.1.1 Bristol-Myers Squibb Company Comapny Information
8.1.2 Bristol-Myers Squibb Company Business Overview
8.1.3 Bristol-Myers Squibb Company Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Bristol-Myers Squibb Company Saxagliptin Product Portfolio
8.1.5 Bristol-Myers Squibb Company Recent Developments
8.2 Minxiang Pharma
8.2.1 Minxiang Pharma Comapny Information
8.2.2 Minxiang Pharma Business Overview
8.2.3 Minxiang Pharma Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Minxiang Pharma Saxagliptin Product Portfolio
8.2.5 Minxiang Pharma Recent Developments
8.3 Taizhou Canova Bio-technology
8.3.1 Taizhou Canova Bio-technology Comapny Information
8.3.2 Taizhou Canova Bio-technology Business Overview
8.3.3 Taizhou Canova Bio-technology Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Taizhou Canova Bio-technology Saxagliptin Product Portfolio
8.3.5 Taizhou Canova Bio-technology Recent Developments
8.4 Tapi Teva
8.4.1 Tapi Teva Comapny Information
8.4.2 Tapi Teva Business Overview
8.4.3 Tapi Teva Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Tapi Teva Saxagliptin Product Portfolio
8.4.5 Tapi Teva Recent Developments
8.5 AstraZeneca
8.5.1 AstraZeneca Comapny Information
8.5.2 AstraZeneca Business Overview
8.5.3 AstraZeneca Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 AstraZeneca Saxagliptin Product Portfolio
8.5.5 AstraZeneca Recent Developments
8.6 Hebei Kangtai Pharma
8.6.1 Hebei Kangtai Pharma Comapny Information
8.6.2 Hebei Kangtai Pharma Business Overview
8.6.3 Hebei Kangtai Pharma Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Hebei Kangtai Pharma Saxagliptin Product Portfolio
8.6.5 Hebei Kangtai Pharma Recent Developments
8.7 Huaman Xincaiiao Keji
8.7.1 Huaman Xincaiiao Keji Comapny Information
8.7.2 Huaman Xincaiiao Keji Business Overview
8.7.3 Huaman Xincaiiao Keji Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Huaman Xincaiiao Keji Saxagliptin Product Portfolio
8.7.5 Huaman Xincaiiao Keji Recent Developments
8.8 Tianjin Scipharmacn
8.8.1 Tianjin Scipharmacn Comapny Information
8.8.2 Tianjin Scipharmacn Business Overview
8.8.3 Tianjin Scipharmacn Saxagliptin Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Tianjin Scipharmacn Saxagliptin Product Portfolio
8.8.5 Tianjin Scipharmacn Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Saxagliptin Value Chain Analysis
9.1.1 Saxagliptin Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Saxagliptin Production Mode & Process
9.2 Saxagliptin Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Saxagliptin Distributors
9.2.3 Saxagliptin Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.